Methods for Isolation and Genetic Analysis of Circulating Tumor DNA in Patient Plasma

  • Tomoya Kawaguchi
  • Will S. Holland
  • Paul H. Gumerlock
Part of the Methods in Molecular Medicine book series (MIMM, volume 85)

Abstract

Nanogram quantities of DNA circulating in blood are present in healthy subjects (1,2). A number of recent studies have shown that tumor DNA is shed in either plasma or serum of cancer patients (3, 4, 5, 6, 7, 8, 9, 10, 11). Further, the plasma of cancer patients is enriched in DNA, up to four times the amount of free DNA compared to plasma from normal controls (4). Specific mutations found in genes in the primary tumors, but not present in the patient’s genomic DNA, can also be identified in the DNA from plasma, demonstrating that the source of the DNA in plasma is the tumor (5,6). Abnormalities detected include microsatellite alterations, immunoglobulin rearrangements, and hypermethylation of several genes (7, 8, 9, 10). Anker, et al.3 reported that 7 of 14 colorectal cancer patients (50%) had a codon 12 K-Ras mutation within their primary tumor, and identical mutations were found in the plasma DNA of 6 of those 7 patients (86%). Mutant DNA was not found in the plasma specimens of 7 patients whose tumors tested negative for K-Ras alterations or in healthy controls (5). Lauschke, et al. also reported that K-Ras mutations were detected in 22 of 30 colorectal tumor tissues, and the same mutation was identified in the serum samples of 6 of the patients (6). Also in that study, mutations of the APC gene were identified in 25 of 65 tumors, and 20 of these 25 patients showed the identical mutation in their serum samples. Genetic abnormalities mirroring those of the primary tumor have also been found in the blood of patients with many other types of cancer, including cancers of the lung, head and neck, breast, liver, and pancreas.

Keywords

Codon Agarose Bromide Electrophoresis MgCl2 

References

  1. 1.
    Steinman, C. R. (1975) Free DNA in serum and plasma from normal adults. J. Clin. Invest. 56, 512–515.PubMedCrossRefGoogle Scholar
  2. 2.
    Raptis, L. and Menard, H. A. (1980) Quantiation and characterization of plasma DNA in normals and patients with systemic lupus erythematosus. J. Clin. Invest. 66, 1391–1399.PubMedCrossRefGoogle Scholar
  3. 3.
    Stroun, M., Anker, P., Maurice, P., Lyautey, J., Lederrey, C., and Beljanski, M. (1989) Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 46, 318–322.PubMedCrossRefGoogle Scholar
  4. 4.
    Shapiro B., Chakrabaty M., Cohn, E., and Leon, S. A. (1983) Determination of circulating DNA levels in patients with benign or malignant gastrointestinal diseases. Cancer 51, 2116–2120.PubMedCrossRefGoogle Scholar
  5. 5.
    Anker, P., Lefort, F., Vasioukhin, V., et al. (1997) K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology 112, 1114–1120.PubMedCrossRefGoogle Scholar
  6. 6.
    Lauschke, H., Caspari, R., Friedl, W., et al. (2001) Detection of APC and K-ras mutations in the serum of patients with colorectal cancer. Cancer Detect. Prev. 25, 55–61.PubMedGoogle Scholar
  7. 7.
    Sozzi, G., Musso, K., Ratcliffe, C., Goldstraw, P., Pierotti, M. A., and Pastorino, U. (1999) Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin. Cancer Res. 5, 2689–2692.PubMedGoogle Scholar
  8. 8.
    Kornacker, M., Jox, A., Vockerodt, M., et al. (1999) Detection of a Hodgkin/Reed-Sternberg cell specific immunoglobulin gene rearrangement in the serum DNA of a patient with Hodgkin’s disease. B. J. Haematol. 106, 528–531.CrossRefGoogle Scholar
  9. 9.
    Esteller, M., Sanchez-Cespedes, M., Rosell, R., Sidransky, D., Baylin, S. B., and Herman, J. G. (1999) Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer. Cancer Res. 59, 67–70.PubMedGoogle Scholar
  10. 10.
    Ivy H. N., Wong, Y. M., Lo, D., et al. (1999) Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 59, 71–73.Google Scholar
  11. 11.
    Levi, S., Urbano-Ispizua, A., Gill, R., et al. (1991) Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res. 51, 3497–3502.PubMedGoogle Scholar
  12. 12.
    Monzó M., Rosell, R., Sánchez, J. J., et al. (1999) Paclitaxel resistance in non-small-cell lung cancer associated with β-tubulin gene mutations. J. Clin. Oncol. 17, 1786–1793.PubMedGoogle Scholar
  13. 13.
    Rodenhuis, S., Boerrigter, L., Top, B., et al. (1997) Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J. Clin. Oncol. 15, 285–291.PubMedGoogle Scholar
  14. 14.
    Shi, X. B., Gumerlock, P. H., Wellman, A. A., et al. (1993) Rapid PCR construction of a gene containing Lym-1 antibody variable regions. PCR Methods Applications 3, 46–53.Google Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2003

Authors and Affiliations

  • Tomoya Kawaguchi
    • 1
  • Will S. Holland
    • 1
  • Paul H. Gumerlock
    • 1
  1. 1.Division of Hematology and Oncology, Department of Internal MedicineUniversity of California Davis Cancer CenterSacramento

Personalised recommendations